Case Comprehensive Cancer Center: Multiple Myeloma trials

The registry lists 25 Multiple Myeloma studies with Case Comprehensive Cancer Center as lead sponsor. 0 are open to participants now and 4 have results posted.

Early Phase 1 1Phase 1 6Phase 2 9Phase 3 3No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
• Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With LenalidomideTerminatedNCT01301963Phase 3Results posted
• Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT01155583Phase 1/2Results posted
• Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT00941720Phase 2Results posted
• Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation ProgramActive, not recruitingNCT05831358Not applicable
• Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCTWithdrawnNCT04685525Not applicable
• Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple MyelomaCompletedNCT04248244Not applicable
• Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering MyelomaWithdrawnNCT03591614Early Phase 1
• Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
• Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family CaregiversCompletedNCT02129569Not applicable
• Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple MyelomaWithdrawnNCT02082405Phase 2
• Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple MyelomaTerminatedNCT01954784Phase 1
• Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
• Music Therapy on Nausea and Pain for Autologous Stem CellCompletedNCT01487031Not applicable
• High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
• Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic CancerTerminatedNCT00918658
• Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
• Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow TransplantationCompletedNCT00281801
• Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
• Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic MalignanciesCompletedNCT00068523Not applicable
• Brostallicin in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00060203Phase 1/2
• Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic AnemiaCompletedNCT00054236Phase 1
• Non-Ablative Allo HSCT For Hematologic Malignancies or SAACompletedNCT00006379Phase 2
• O6-benzylguanine And Carmustine in Treating Patients With Multiple MyelomaCompletedNCT00004072Phase 2
• High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003116Phase 2